CHSJ

Curr Health Sci J, vol. 46, no. 3, 2020

Long Term Survivor with Erlotinib in Metastatic Lung Cancer-Squamous Cell Carcinoma Subtype

[Case Report]

B.I. VATU(1), T. CRISTIAN(2), S. ARTENE(3), A. STIUCA(1)


(1)Emergency County Hospital of Slatina, Romania,
(2)Emergency County Hospital of Alexandria, Romania,
(3)Department of Biochemistry, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

Currently, data that supports the clinical benefit of agents targeting the epidermal growth factor receptor (EGFR) in the therapy of squamous cell carcinoma (SCC) histologic version of the lung cancer (LC) is insufficient. In the following report we present the case of a patient treated with erlotinib for SCC NSCLC. At the time of initiation, there were no available guidelines recommendations regarding the EGFR status in for initiation of EGFR tyrosine kinase inhibitors (TKIs) therapy for NSCLC, thus the sample was never tested for the EGFR mutational status. Not widely used in the treatment of SCC, EGFR-TKIs remain a valid therapeutic option in selected groups of patients.


Keywords: Non-small cell lung cancer, TKI, EGFR, EGFR-TKIs, erlotinib, targeted therapy



Corresponding: Bogdan Ionel Vatu, Emergency County Hospital of Slatina, Romania, e-mail: bogdan.vatu@yahoo.com


DOI 10.12865/CHSJ.46.03.13 - Download PDF
current issue cover Download cover
Download contents

Journal archive